2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.
Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.
Due to this analysis, it is important for the patients who are candidates for sipuleucel-T to receive it early in their treatment course since that is where the best outcomes were seen, explains Sartor.
This could lead to the hypothesis that perhaps African-American patients are more responsive to immunotherapy across many different cancer types, but this needs to be proven, states Sartor.